Menu
Previous
Next
Medicines at the Nexus of Metabolism Immunity
“Path to End Patient Suffering”
Nirogy Story & Vision
“Nirogy” means “without illness” in Sanskrit. Our vision is to create a path to end patient suffering. Nirogy has been trying to unravel the intricate symbiotic communication network among various cell types in the tumor and immune microenvironment (TIME)…
Transformative Science
A pioneer in the metabolic solute carrier transporter (SLCT) space, a largely untapped target class, for hard-to-treat diseases such as cancer, autoimmunity, and inflammation…
Executive Team
An experienced team of science, business, and operations united by a common goal.
Nirogy News
Nirogy Therapeutics to Present at AACR Annual Meeting 2022
Two posters highlighting preclinical data of a small molecule development candidate with a novel mechanism of immune activation in the TME and cancer cell intrinsic killing demonstrate significant efficacy across …
Nirogy Therapeutics Presented at Keystone Symposia on Cancer Immunotherapy: Decoding the Cancer Immunity Interactome. British Columbia, CANADA
Framingham, MA, March 30, 2022, Nirogy Therapeutics, a biopharmaceutical company focused on oncology and Immune diseases, presented at the Cancer Immunotherapy: Decoding the cancer immunity interactome, Keystone Conference that took …
Nirogy Therapeutics Appoints Simon Pedder, Ph.D., as Chief Executive Officer
Appointment Strengthens Leadership and Expertise to Drive Lead Oncology Program into Phase 1 Clinical Development Founding Chief Executive Officer Dr. Vincent Sandanayaka transitions to role of President and Chief Scientific …
